xMAP® SARS-CoV-2 Antibody Testing (RUO)


Reliable SARS-CoV-2 detection starts with robust testing

xMAP® SARS-CoV-2 Multi-Antigen IgG Assay

Have confidence in your COVID-19 antibody test.

In these uncertain times, laboratories need to have confidence in COVID-19 antibody test results—which is why Luminex has developed a comprehensive SARS-CoV-2 antibody assay. Using a combination of robust internal controls and highly-specific antigens, the xMAP® SARS-CoV-2 assay enables the rapid and reliable detection of SARS-CoV-2 antibodies in plasma and serum samples.

xMAP® SARS-CoV-2 Multi-Antigen IgG Assay (RUO)

The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay (RUO) is a multiplex, microsphere-based, highly sensitive and specific assay that detects the presence or absence of antibodies against three different SARS-CoV-2 antigens.

The xMAP SARS-CoV-2 Multi-Antigen IgG Assay features:

  • Broad Coverage: Detects IgG antibodies against 3 SARS-CoV-2 antigens, providing comprehensive results:
    • S1 subunit of the spike protein
    • Receptor Binding Domain (RBD) of the spike protein
    • Nucleocapsid protein
  • Flexible Throughput: Test up to 96 samples per run in less than 3 hours to meet your throughput needs.
  • Versatile System Options: Can be used on MAGPIX®, Luminex® 200™, and FLEXMAP 3D® Systems, so you can use the platform that best fits your lab.
  • Common Sample Types: Designed for use with plasma and serum samples, eliminating the need to implement additional collection protocols.
xMAP® SARS-CoV-2 Multi-Antigen IgG Assay Icon

xMAP® SARS-CoV-2 Multi-Antigen IgG Assay Workflow

xMAP® SARS-CoV-2 Multi-Antigen IgG Assay Workflow Step 1

Step 1

Add sample and bead mix to the well and incubate for 60 min at room temperature.

xMAP® SARS-CoV-2 Multi-Antigen IgG Assay Workflow Step 2

Step 2

Add detection antibody mix to the well and incubate for 60 min at room temperature.

xMAP® SARS-CoV-2 Multi-Antigen IgG Assay Workflow Step 3

Step 3

Resuspend sample and transfer plate to instrument.

xMAP® SARS-CoV-2 Multi-Antigen IgG Assay Workflow Step 4

Step 4

Read on Luminex Instrument.

Performance

  Days From
Symptom Onset*
PPA 95% Cl NPA 95% Cl
MAGPIX® (NxTAG®-enabled)
Serum ≤7 71.1% 55%–83% 100.0% 99%–100%
8-14 71.4% 50%–86%
>14 96.2% 87%–99%
Plasma ≤7 100.0% 70%–100% 99.2% 96%–100%
8-14 81.8% 52%–95%
>14 96.6% 83%–99%
MAGPIX®
Serum ≤7 71.1% 55%–83% 100.0% 99%–100%
8-14 80.0% 58%–92%
>14 98.1% 90%–100%
Plasma ≤7 100% 70%–100% 99.2% 96%–100%
8-14 90.0% 60%–98%
>14 96.6% 83%–99%
Luminex® 200™
Serum ≤7 73.7% 58%–85% 100.0% 99%–100%
8-14 80.0% 58%–92%
>14 98.1% 90%–100%
Plasma ≤7 100.0% 70%–100% 99.2% 96%–100%
8-14 90.0% 60%–98%
>14 96.4% 82%–99%
FLEXMAP 3D®
Serum ≤7 71.1% 55%–83% 100.0% 99%–100%
8-14 80.0% 58%–92%
>14 98.1% 90%–100%
Plasma ≤7 100.0% 70%–100% 99.2% 96%–100%
8-14 90.0% 60%–98%
>14 96.4% 82%–99%
*or days from molecular positive

The performance was determined separately for each instrument (Luminex 200, MAGPIX NxTAG-enabled, MAGPIX, and FLEXMAP 3D Systems) and each matrix (serum and plasma).

Luminex’s xMAP® Technology combines advanced fluidics, optics, and digital signal processing with proprietary microsphere technology to deliver powerful multiplex assay capabilities. Featuring a flexible, open-architecture design, xMAP Technology can be configured to perform a wide variety of protein and nucleic acid assays accurately, affordably, and quickly.

xMAP Technology enables multiplexing of biological assays—reducing time, labor, and costs compared to traditional methods such as ELISA, Western blot, PCR, and microarrays. Systems using xMAP Technology offer robust detection due to the surface chemistry of Luminex’s color-coded beads, or microspheres. Using multiple lasers or LEDs for detection and high-speed digital-signal processors, the analyzer reads multiplex assay results by reporting the reactions occurring on each individual microsphere—enabling you to get more data with less sample.

Video Thumbnail
Getting Started with xMAP® Technology
Have confidence in your COVID-19 antibody test. In these uncertain times, laboratories need to have confidence in COVID-19 antibody test results—which is why Luminex has developed a comprehensive SARS-CoV-2 antibody assay. Using a combination of robust internal controls and highly-specific antigens,

xMAP Instruments

Luminex offers three different xMAP-based instrumentsMAGPIX®, Luminex® 200™, and FLEXMAP 3D®—covering a broad range of laboratory and budgetary needs. The xMAP® SARS-CoV-2 antibody assay can be used on all three of these platforms.

Whether you are looking for an instrument that is easy to learn and use, or a system for high-throughput applications that offers fast read times and integration with front-end automation systems—there is a Luminex multiplexing platform to support your research needs.

Ordering Information

xMAP® SARS-CoV-2 Multi-Antigen IgG Assay

Product Name Description Registration Status Part Number
xMAP® SARS-CoV-2 Multi-Antigen IgG Assay 96 Tests RUO 30-00127
xMAP® SARS-CoV-2 Multi-Antigen IgG Assay Accessory Kit* Data Analysis Software and Package Inserts RUO CN-SW77-01
xMAP® SARS-CoV-2 IgG Control Kit 50 µL RUO 30-00129
* One-time order only

(RUO) This product is for Research Use Only. Not for use in diagnostic procedures.